MedPath

A study to find the role of N acetyl cysteine given intraductally in the submandibular gland on reducing radiotherapy related side effects such as swallowing difficulties and voice changes in patients with oropharyngeal cancer undergoing radiotherapy.

Not Applicable
Conditions
Health Condition 1: C10- Malignant neoplasm of oropharynx
Registration Number
CTRI/2020/10/028521
Lead Sponsor
ENT Department
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Clinically, radiologically and biopsy proven cases of oropharyngeal cancer,

2.Planned for radical radiotherapy,

3.Patients giving written informed consent

Exclusion Criteria

1.Patient not giving consent,

2. <18 years, >70 years,

3.Decreased mouth opening (Trismus),

4.Having undergone a total laryngectomy,

5.History of radiotherapy in Head and Neck area

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in swallowing using Fibre-optic endoscopic evaluation of swallowing (FEES) and M.D. Anderson Dysphagia Inventory (MDADI) score. <br/ ><br> <br/ ><br>Changes in voice using Voice Handicap Index-10 (VHI-10) score. <br/ ><br>Timepoint: 0, 3 months
Secondary Outcome Measures
NameTimeMethod
Change in the salivary flow rate, pH and viscosity.Timepoint: 0, 3 months
© Copyright 2025. All Rights Reserved by MedPath